Revenue (Tables)

3 Months Ended

Mar. 31, 2018

Revenue from Contract with Customer [Abstract]

Impact of ASC 606 in Current Period [Table Text Block]

The following tables represent the amounts by which each financial statement line item is affected in the current year as a result of applying ASC Topic 606 (in thousands):

	For the three months ended March 31, 2018
	As Reported		Without Adoption of ASC 606		Effect of Adoption
Revenue	$	372,033	$	374,045	$	(2,012	)
Cost of goods sold	$	223,032	$	223,011	$	21
Gross Profit	$	149,001	$	151,034	$	(2,033	)

	As of March 31, 2018
	As Reported	Without Adoption of ASC Topic 606		Effect of Adoption
Prepaid expenses and other current assets	32,406	$	35,529	$	(3,123	)
Accrued liabilities	116,448	$	129,932	$	(13,484	)
Deferred income taxes	20,073	$	22,072	$	(1,999	)

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by geography (in thousands):

	For the three months ended March 31,
Geography	2018		2017 (1)
EMEA	$	39,524	$	24,953
APAC	18,624		11,416
LATAM	13,093		6,477
North America	19,135		11,561
Other	80		—
Total Foreign	90,456		54,407
United States	281,577		193,332
Total Revenues	$	372,033	$	247,739

The following table represents our revenues disaggregated by product (in thousands):

	For the three months ended March 31,
Product line	2018		2017 (1)
Infusion Consumables	$	119,911	$	75,713
IV Solutions	144,440		97,370
Infusion Systems (2)	93,439		46,670
Critical Care	14,243		12,396
Other	—		15,590
Total Revenues	$	372,033	$	247,739

Contract with Customer, Asset and Liability [Table Text Block]

The following table presents our changes in the contract balances for the three months ended March 31, 2018 (in thousands):

	Contract Liabilities
Beginning balance, January 1, 2018	$	(7,066	)
Equipment revenue recognized	288
Equipment revenue deferred due to implementation	(1,558		)
Software revenue recognized	655
Software revenue deferred due to implementation	(4,080		)
Ending balance, March 31, 2018	$	(11,761	)